NCT06511908View on ClinicalTrials.gov

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 6, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
SuicideDepressive Disorder, Treatment-ResistantKetamineMolecular Mechanisms of Pharmacological ActionNeurotransmitter AgentsExcitatory Amino Acid AgentsPhysiological Effects of DrugsDepressive Disorder, MajorDepressive DisorderDepressionMental DisordersMood DisordersBehavioral Symptoms
Interventions
DRUG

(2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)

Arm 1 and 2 Experimental Intervention

DRUG

Placebo

Arm 1 and 2 Control Intervention

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Mental Health (NIMH)

NIH